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the period 1997 to 1999 was included in the analysis of effectiveness. Of these, 602 patients had received EDA and 42 had received PCIA. However, data were incomplete for 33 patients (all in the EDA group) and they were excluded from the analysis. Thus, the final sample comprised 569 patients (50% women) in the EDA group and 42 patients (57% women) in the PCIA group. The mean age of the patients was 57 (+/-17) years in the EDA group and 48 (+/-16) years in the PCIA group.
Study design
This was a retrospective cohort study that was carried out in Sweden. The number of centres involved was not stated. The patients were followed for 3 days, which corresponded to the duration of treatment. No patient in the final sample was lost to follow-up. Blinding was not carried out.
Analysis of effectiveness
All patients included in the final study sample were considered in the analysis of effectiveness. The primary outcome measures were the probabilities of the following: an unsuccessful attempt with EDA and thus treatment with PCIA; a poor effect with EDA and thus re-insertion of epidural catheter; a successful attempt with EDA; a poor effect or side effect with EDA and thus treatment with PCIA; a poor effect and side effect with either treatment, and thus change in treatment to bolus doses of morphine; minor problems with the epidural catheter, motor blockade and numbness, but continued treatment; accidental dislocation of epidural catheter; fulfilled treatment; pain during treatment, thus further intervention; no pain during treatment; nausea and vomiting (with and without pharmacological treatment); and respiratory depression (no pharmacological treatment needed).
The proportion of patients who were pain-free was also assessed using a visual analogue scale (VAS) to monitor pain intensity every 3 hours. This was the main outcome measure used in the economic analysis. Patient characteristics were reported for both groups, but the baseline comparability of the study groups was not discussed.
Effectiveness results
The probability values were as follows: 0.014 for an unsuccessful attempt with EDA and thus treatment with PCIA; 0.012 for a poor effect with EDA and thus re-insertion of epidural catheter; 0.974 for a successful attempt with EDA; 0.09 for a poor effect or side effect with EDA and thus treatment with PCIA; The proportion of patients who were pain-free was only reported in the graphical representation of the decision tree, and this depended on the different pathways followed by the patients. In particular, patients who received PCIA and fulfilled the treatment had a probability of 60% for 3 pain-free days, 17.5% for 2 pain-free days, 0% for 1 pain-free day and 22.5% for 0 pain-free days. Patients who received EDA without side effects and with no need for intervention had a probability of 93% for 3 pain-free days, 5% for 2 pain-free days, 1% for 1 pain-free day and 1% for 0 pain-free days.
The other pathways were, in general, characterised by a lower probability of having pain-free days.
Clinical conclusions
The probability values derived from the clinical database were used as clinical inputs in the decision model.
Modelling
A decision tree model was constructed to assess the costs and benefits of the two pain treatment strategies. The two main branches of the tree represented EDA versus PCIA. The most relevant pathways and events included completed treatment, change of treatment, unsuccessful attempt to introduce epidural catheter, early dislocation of catheter, reinsertion of epidural catheter, and the need for additional pain treatment. A graphical representation of the tree was provided in the paper. The key assumption of the model was that the costs and the main clinical benefit of the treatments had a linear relationship.
Measure of benefits used in the economic analysis
The summary benefit measure used was the expected number of pain-free days for each treatment strategy. This was obtained using a modelling approach. Pain-free days were estimated both at rest and during activity.
Direct costs
The perspective of the cost analysis was not explicitly stated. The cost categories taken into consideration were personnel, material, drugs and postoperative care. The unit costs were not presented separately from the quantities of resources used since 3-day costs for each item were reported. The costs were derived from the hospital administration and from the hospital pharmacy. The costs of postoperative care came from official tariffs. Resource consumption was estimated from interviews with the staff. The costs were weighted on the basis of event probabilities derived from the clinical database. Discounting was not relevant as the costs were incurred during a very short timeframe. The price year was 2005.
The effectiveness evidence came from a cohort study. The retrospective nature of the study limits the validity of the primary estimates, and the impact of selection bias or confounding factors cannot be ruled out. However, the authors considered smaller matched groups of patients in the sensitivity analysis in order to improve the internal validity of the study. The method of sample selection was not clearly described, although the inclusion of consecutive patients increased the robustness of the study. Further, there was no evidence (e.g. power calculations) of whether the sample size was appropriate. The baseline comparability of the study groups in terms of patient demographics and other clinical aspects was not discussed, and this might further limit the robustness of the clinical evidence. The number of medical centres involved in the analysis was not explicitly stated. These issues should be considered when assessing the validity of the clinical study.
Validity of estimate of measure of benefit
The summary benefit measure was specific to the disease considered in the study. It would not comparable with the benefits of other health care interventions. The authors stated that the impact of the pain treatments on quality of life was not investigated on account of the very short timeframe of the analysis. However, it was acknowledged that painfree days were not an appropriate measure with which to capture the impact of the interventions on patient health.
Validity of estimate of costs
The cost analysis included the hospital costs associated with post-surgery treatment. A breakdown of the cost items was not reported, and information on the unit costs and quantities of resources used was not given. Thus, it would be difficult to replicate the analysis in other settings. The cost estimates were treated deterministically in that no statistical test was undertaken. However, the impact of changes in uncertain cost estimates was investigated in the sensitivity analysis. The sources of the data were reported. The price year was given, which will facilitate reflation exercises in other time periods.
